ACT-A Facilitation Council announces funding gap of US$27.2 billion, asks countries not to compete with COVAX vaccine contracts

The Facilitation Council of the Access to COVID-19 Tools Accelerator (ACT-A) had its fourth meeting on February 9, 2021, to discuss its 2021 agenda and needs, including closing the funding gap of US$27.2 billion for 2021.

The World Health Organization (WHO) Director-General, Dr. Tedros Adhanom Ghebreyesus, co-hosted and began his introductory remarks by welcoming the newly-joined US under President Joe Biden to ACT-A. 

Ghebreyesus stressed that more than 90% of countries currently administering COVID-19 vaccines are wealthy, and 75% of all doses given have been given in just ten countries. Nearly 130 countries, he said, have not administered a single dose.

ACT-A and the COVAX Facility were created as part of global efforts coordinated by the WHO and Gavi, the Vaccine Alliance, among others, in order to increase access to vaccines and promote vaccine equity internationally, and these goals are being threatened, said Ghebreyesus.

He called for:

  1. Full financing of ACT-A and COVAX: The financing gap is at more than US$27.2 billion for 2021. He called on the Organisation for Economic Co-operation and Development (OECD) and Development Assistance Committee (DAC) countries to commit a proportion of stimulus financing and to unlock capital in multilateral development banks to help close the gap.
  2. Respect for COVAX contracts from all countries and a non-competition commitment: He referred here to countries who continue to sign bilateral vaccine deals while many nations have no vaccine doses at all. Ghebreyesus reiterated WHO's goal that the vaccination of health workers should be in progress in all countries within the first 100 days of 2021, which means that countries with more doses need to share and donate doses before going on to vaccinate their lower-risk populations. He warned that if COVID-19 is not suppressed globally, that variants of the virus could result in the world "back at square one".
  3. An urgent increase in manufacturing to increase the volume of vaccines: This could include "innovative partnerships including tech transfer, licensing and other mechanisms to address production bottlenecks".

Experts have warned that all countries need to take an "internationalist", not nationalist, approach to vaccination rollout and tacking COVID-19, otherwise experts fear that some low-income countries may not receive vaccines until 2024.

Visuals from the 'ACT-A Prioritized Strategy & Budget for 2021' presentation illustrate the contributors of a total of US$6.0 billion to ACT-A, as of February 3, and the breakdown of the US$27.2 billion needed for 2021. According to an update as of February 12, ACT-A has an additional US$4.0 billion in projected funding, so the US$27.2 billion funding gap "will be reduced to US$23.2 billion as projected funds are operationalized."

Transcript - WHO

Event website - WHO